Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT07230977 | GenSci139 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 280 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07251166 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 170 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05306132 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 | recruiting | Phase 1 | 150 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 252 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06712680 | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes | recruiting | Phase 1 / Phase 2 | 115 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07292402 | JSKN022 in Subjects With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 225 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04936178 | A Study of NB003 in Patients With Advanced Malignancies | completed | Phase 1 | 258 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 6 | Dec 22, 2025 | clinicaltrials |
| NCT05508334 | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 41 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05240898 | A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors | completed | Phase 1 | 116 | Hoffmann-La RocheINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05287399 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | completed | Phase 1 | 18 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | terminated | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT06727812 | Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors | recruiting | Phase 1 | 206 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 194 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05566574 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | active not recruiting | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT07266285 | BTM-3566 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Bantam PharmaceuticalsINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07288957 | A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors(ABSK131-101) | recruiting | Phase 1 | 266 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 177 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285395 | AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study | recruiting | Phase 1 | 12 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05159700 | A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 39 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281326 | A Study of AK138D1 in Advanced Malignant Tumors | recruiting | Phase 1 | 200 | AkesoINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04898543 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 50 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06375187 | A Study of GC203 TIL in Advanced Malignant Solid Tumors(KUNLUN-001) | recruiting | Phase 1 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | completed | Phase 1 | 168 | AbbVieINDUSTRY | 10 | Dec 10, 2025 | clinicaltrials |
| NCT05417750 | A Phase I Study of GC101 TIL in Advanced Solid Tumors(MIZAR-001) | completed | Phase 1 | 43 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07274085 | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | recruiting | Phase 1 | 96 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07274449 | Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors(NK) | active not recruiting | Phase 1 / Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07275853 | Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05338658 | Study of PAT in Patients With Solid Tumor Cancers | recruiting | Phase 1 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06241456 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | recruiting | Phase 1 | 351 | Fate TherapeuticsINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07272590 | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05105971 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China | completed | Phase 1 | 30 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05155722 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors | completed | Phase 1 | 59 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06341114 | A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 112 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03968653 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Debiopharm International SAINDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | terminated | Phase 1 | 67 | Debiopharm International SAINDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT05147350 | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors(MINOTAUR) | terminated | Phase 1 | 38 | Debiopharm International SAINDUSTRY | 4 | Dec 5, 2025 | clinicaltrials |
| NCT06735144 | Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07265921 | A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors(Solid Tumors) | recruiting | Phase 1 | 232 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04021043 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05134948 | A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors(RELATIVITY 059) | completed | Phase 1 / Phase 2 | 24 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 3, 2025 | clinicaltrials |
| NCT06703177 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 876 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 24, 2025source: clinicaltrials